Long-term clinical outcomes in survivors of SARS and MERS
Citation: Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. Journal of Rehabilitation Medicine. 2020 May 25;52(5):jrm00063.
What is this? Some patients with COVID-19 will become critically ill and may experience long-term complications from their illness. Research on the long-term clinical outcomes of patients with other coronaviruses (SARS and MERS) might provide useful information for healthcare providers and policy makers.
In this rapid review, the authors searched for studies on the long-term (> 3 month) clinical complications for survivors of SARS and MERS after hospitalization and intensive care unit admission. They did not restrict their searches by date of publication and did the search in March 2020. They included 28 studies, including 26 studies on SARS and 2 on MERS.
What was found: At the time of this review, the included studies showed that health-related quality of life was considerably reduced in survivors of SARS and MERS even 12 months after discharge.
At the time of this review, the included studies showed that common complications among survivors included lung function abnormalities, reduced exercise capacity and psychological consequences, such as depression, post-traumatic stress disorder and anxiety.
Based on the evidence available from studies of patients with SARS and MERS, the review authors concluded that rehabilitation clinicians and services should anticipate similar long-term health problems in survivors of COVID-19, investigate them accordingly and plan suitable and timely treatments to enable their best possible recovery and quality of life.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.